OncoGenex Cash To Last Into 2010
Luke Timmerman3/11/09
OncoGenex Pharmaceuticals, the Bothell, WA-based developer of cancer drugs, said today it had $12.4 million in cash and investments left at the end of 2008, which ought to be enough to fund its operations through February 2010. OncoGenex (NASDAQ: OGXI) hopes to use the cash to further develop its experimental prostate cancer drug which showed in a clinical trial in December that it helped patients live about 10 months longer than if they got chemotherapy alone.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
